Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
IPO Year:
Exchange: NYSE
Website: stryker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $450.00 | Buy | Citigroup |
| 12/2/2024 | $370.00 → $445.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/10/2024 | $405.00 | Outperform | Wolfe Research |
| 5/30/2024 | $372.00 | Neutral | Goldman |
| 5/22/2024 | $392.00 | Hold → Buy | Needham |
| 1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
| 10/20/2023 | $345.00 | Buy | ROTH MKM |
| 9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
| 3/29/2023 | $287.00 | Neutral | UBS |
| 1/25/2023 | Sector Weight | KeyBanc Capital Markets |
Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its second quarter 2025 results. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after
Streamlining total ankle replacement with data-driven implants and surgical flexibility Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/Stryker's
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 13.4 % (0.8) % 14.2 % 3.5 % 10.7 %Orthopaedics
Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time. A live webcast and replay of the presentation will be accessible on Stryker's website at www.stryker.com, and it will be archived on the Investor Relations page. About Stryker Stryker is a global leader in medical technologies and, together wi
Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE:SYK). The business will operate as a standalone company under the name VB Spine, LLC ("VB Spine"). VB Spine is advancing toward the completion of its acquisition of Stryker's international spine businesses, pending satisfaction of legal and regul
Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. "The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth," said Kevin Lobo, Chair and CEO, Stryker. "We remain committed to the spine space through our Interventional Spine, Neurotechnology and Enabling Technologies businesses, as well as our strategic partnership with
Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel "Manny" Maceda for election to the company's board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and CEO from 2018 to 2024. In that role, he led Bain's global strategy and operations across more than 50 offices, driving the firm's transformation to strengthen digital capabilitie
S-8 - STRYKER CORP (0000310764) (Filer)
SD - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
DEFA14A - STRYKER CORP (0000310764) (Filer)
DEF 14A - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
144 - STRYKER CORP (0000310764) (Subject)
3 - STRYKER CORP (0000310764) (Issuer)
4/A - STRYKER CORP (0000310764) (Issuer)
4/A - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
3 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00
Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously
Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
Canaccord Genuity upgraded Stryker from Hold to Buy and set a new price target of $360.00 from $315.00 previously
ROTH MKM initiated coverage of Stryker with a rating of Buy and set a new price target of $345.00
BofA Securities upgraded Stryker from Neutral to Buy and set a new price target of $315.00 from $310.00 previously
UBS initiated coverage of Stryker with a rating of Neutral and set a new price target of $287.00
KeyBanc Capital Markets initiated coverage of Stryker with a rating of Sector Weight
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 13.4 % (0.8) % 14.2 % 3.5 % 10.7 %Orthopaedics
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk
Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 10.6 % (0.5) % 11.1 % 1.0 % 10.1
Portage, Michigan, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable January 31, 2025 to shareholders of record at the close of business on December 31, 2024, representing an increase of 5.0% versus the prior year and previous quarter. "We continue to deliver strong financial results, and consistent with our capital allocation priorities we are raising our dividend 5.0%," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. "We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life." The addition of Vertos Me
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care. ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually ar
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stry
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
EMERYVILLE, Calif., Sept. 12, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of Brent D. Lang, former Chairman and CEO of Vocera Communications, to its Board of Directors. Lang brings over three decades of healthcare and technology experience, having led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE:SYK). His strategic vision and proven leadership will guide Eko as it continues to innovate and expand its platform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment of Stuart F. Simpson as its president and chief executive officer. Mr. Simpson's decades of experience in the medical device industry, particularly his deep understanding of the orthopedics industry and orthopedic surgical robots, makes him the ideal person to lead THINK Surgical. Mr. Simpson had a successful 24-year career at Stryker Corporation (NYSE:SYK) holding roles of increasing responsibility in Europe, Asia Paci
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology PLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors. Dr. M